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Abstract
Background: Plasmodium vivax shows a small prevalence in West and Central Africa due to the high prevalence of Duffy
negative people. However, Duffy negative individuals infected with P. vivax have been reported in areas of high prevalence
of Duffy positive people who may serve as supply of P. vivax strains able to invade Duffy negative erythrocytes. We
investigated the presence of P. vivax in two West African countries, using blood samples and mosquitoes collected during
two on-going studies.
Methodology/Findings: Blood samples from a total of 995 individuals were collected in seven villages in Angola and
Equatorial Guinea, and 820 Anopheles mosquitoes were collected in Equatorial Guinea. Identification of the Plasmodium
species was achieved by nested PCR amplification of the small-subunit rRNA genes; P. vivax was further characterized by csp
gene analysis. Positive P. vivax-human isolates were genotyped for the Duffy blood group through the analysis of the DARC
gene. Fifteen Duffy-negative individuals, 8 from Equatorial Guinea (out of 97) and 7 from Angola (out of 898), were infected
with two different strains of P. vivax (VK210 and VK247).
Conclusions: In this study we demonstrated that P. vivax infections were found both in humans and mosquitoes, which
means that active transmission is occurring. Given the high prevalence of infection in mosquitoes, we may speculate that
this hypnozoite-forming species at liver may not be detected by the peripheral blood samples analysis. Also, this is the first
report of Duffy negative individuals infected with two different strains of P. vivax (VK247 and classic strains) in Angola and
Equatorial Guinea. This finding reinforces the idea that this parasite is able to use receptors other than Duffy to invade
erythrocytes, which may have an enormous impact in P. vivax current distribution.
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Introduction
Plasmodium vivax has been neglected by the scientific community
since it has been seen as a ‘‘benign’’ parasite. Nowadays this
scenario has changed and the infection caused by P. vivax gained
higher importance, firstly because it has a very wide distribution,
being found both in tropical and subtropical areas [1,2,3]; and
secondly because of the high number of clinical cases reported,
ranging from 70 million to 300 million [2,4,5]. Although clinical
symptoms are usually considered as not severe, some reports
documented cases of severe disease and even death [6,7,8,9].
This parasite has traditionally shown a small prevalence in West
and Central Africa, attributed to the high prevalence of Duffy
negative people [Fy(a2b2)] who are described as being resistant
to P. vivax infection [10,11]. Culleton et al. [12] performed a study
including nine endemic countries of West and Central Africa using
a high sensitive PCR-based protocol for the detection and
identification of Plasmodium species reporting only one case out
of 2588 individuals infected with P. vivax - one Duffy-positive
individual from Sa˜o Tome´. Although the exact prevalence of P.
vivax in Africa is unknown, this parasite tends to be endemic in
countries of East Africa, like Sudan, Somalia and Ethiopia, where
the majority of the population is Duffy-positive.
The Duffy antigen, also called Duffy antigen receptor for
chemokines (DARC), is a multimeric red cell membrane protein
organized into seven transmembrane domains, and it is the unique
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known erythrocyte receptor for P. vivax invasion. DARC-coding
gene is polymorphic with multiple alleles as the codominant FY*A
and FY*B, which encode for the two antigens – Fya and Fyb. Four
genotypes are possible as a result of the combination of the major
alleles, Fy(a+b+), Fy(a+b2), Fy(a2b+) and Fy(a2b2) [13,14,15].
The first three correspond to a Duffy-positive phenotype, mostly
prevalent in Asian and in Caucasian populations and the last one
correspond to the Duffy-negative phenotype, mainly prevalent in
African people, who are consequently resistant to P. vivax infection.
The Fy(a2b2) genotype results from a point mutation, -33T.C,
in the promoter region of allele FY*B, in the GATA box region
[13].
Recent data showed that Duffy binding protein, the main
vaccine candidate for P. vivax [16,17], seems no longer to protect
against P. vivax infection. Rosenberg [18] hypothesized that P. vivax
could infect Duffy negative erythrocytes, since there were reports
of European travellers and immigrants from West and Central
Africa who were infected with P. vivax [19,20,21]. In fact, there are
now other reports that seem to support this hypothesis [18].
In a case-control study conducted in Kenya, an East African
country, with children with severe malaria caused by Plasmodium
falciparum, it was found that there were children infected with P.
vivax VK247 despite being Duffy-negative [22]. Similar results
were found in the Amazon region in Brazil [23,24] and more
recently in Madagascar [25]. These new data suggest that P. vivax
may be evolving by using alternative receptors to bind and invade
erythrocytes or it may be a ‘‘vivax-like’’ that do not require Duffy
antigen for the invasion [26].
Currently, three different strains of P. vivax have been described –
classic P. vivax (also called P. vivax VK 210), P. vivax VK 247 and P.
vivax-like. These strains, although morphologically similar, differ in the
central portion of circunsporozoite surface protein (csp), an abundant
polypeptide present at the sporozoite surface [27]. The variant
VK247 was first described by Rosenberg et al. [28] in isolates from
Thailand and differs from the P. vivax classic in the nonapeptide
repeat units of the central portion of CSP gene: ANGA(G/D)(N/
D)QPG in P. vivax VK247 and GDRA(A/D)GQPA in P. vivax classic
(described in [29]). Qari et al. [26] identified the strain P. vivax-like,
characterised by having a 11-mer repeat sequence, APGNQ(E/
G)GGAA in the central portion of the CSP gene.
With new cases of P. vivax infections appearing every day,
especially in countries where this parasite has not been reported
before, it becomes essential not to underestimate it, since P. vivax
may be swiftly evolving and infecting people that were thought to
be protected.
The aims of this study were to investigate the presence of P. vivax
in Angola and in Equatorial Guinea, using blood samples and
mosquitoes, and analyze the presence of P. vivax infection in Duffy-
negative individuals.
Methods
Ethics statement
Each person (or parent) was informed of the nature and aims of
the study and told that participation was voluntary and that they
could withdraw from the study at any time. Blood samples were
collected after informed consent from all donors (parents or
guardians respond on behalf of children). In Equatorial Guinea,
written consent was not obtainable because of the community-
wide mistrust of signing any official forms and the low level of
literacy in the population. Viewing this, written consent was only
assented by population in case of the legal guardians of the
recruited children and only non-documented oral consent was
requested on adults. The study was approved by the Ethical
Committee of the Equatorial Guinea’s Ministry of Health and
Social Welfare, the National Malaria Control Programme and the
local health authorities from these villages, which accepted this
constraint and did not find bio-ethical impediments to disallow the
study. In Angola, written informed consent was obtained from
each person (or parent/guardian) and the study was approved by
the Ethical Committee of the Angola’s Ministry of Health. Ethical
clearance was also given by the Ethical Committees of IHMT and
the ISCIII, according to EU norms.
Sampling
Blood samples were collected as part of two on-going studies in
Angola and Equatorial Guinea (see figure 1).
Angola samples were collected in Gabela (10uS519/14uE229),
Porto Amboim (10uS439/13uE469), Kissala-Sumbe (11uS129/
13uE509), Praia-Sumbe (11uS129/13uE509) [Kuanza Sul province]
and Funda (8uS509/13uE339) [Bengo province] between June
2006 and May 2007. In these two provinces malaria is
mesoendemic stable and the climate is tropical, characterised by
a wet and warm season, from September to April, and a dry and
cold season, from May to August. In each village, blood samples
were collected by fingerprick on filter paper, from asymptomatic
children older than 2 months.
In Equatorial Guinea, blood samples and mosquito specimens
were collected from 20 households in two different villages -
Miyobo (1uN459/10uE109) in May and August of 2005 and
Ngonamanga (2uN99/9uE489) in February and May of 2005. The
two villages present different ecological characteristics: Miyobo is
located in the interior of the country in a forested area, while
Ngonamanga is a coastal area. In both, malaria is classified as
hyperendemic, and it is possible to distinguish four seasons, two
dry seasons from December to March and from July to
September; and two wet seasons, one more intense from
September to November and the other from March to the end
of June. In each household, blood fed resting mosquitoes were
collected early in the morning (5.00–7.00am), followed by blood
sample collection by fingerprick from all inhabitants, during four
consecutive days. Mosquitoes were kept in paper-cups corre-
sponding to each house/room for 8 days to enable the
development of oocysts from infections acquired the night prior
to collection. Head/thorax and abdomen from each mosquito
were kept separately for subsequent molecular processing.
Author Summary
Recent reports of Plasmodium vivax infections, the most
widely distributed species of human malaria, show that
this parasite is evolving and adapting, becoming not only
more aggressive but also more frequent in countries
where it was not present in the past, becoming, therefore,
a major source of concern. Thus, it is extremely important
to perform new studies of its distribution in West and
Central Africa, where there are few reports of its presence,
due to the high prevalence of Duffy-negative individuals.
The aim of this study was to investigate the presence of P.
vivax in Angola and in Equatorial Guinea, using blood
samples and mosquitoes. The results showed that P. vivax
seems to be able to invade erythrocytes using receptors
other than Duffy, and this new capacity is not exclusive to
one strain of P. vivax, since we have found samples
infected with two different strains: VK247 and classic.
Additionally we demonstrated that the parasite has a
greater distribution than previously thought, calling for a
reevaluation of its worldwide distribution.
Duffy Negative Antigen and P. vivax in West Africa
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Sample collection and DNA extraction
Blood samples from a total of 995 individuals (898 from Angola
and 97 from Equatorial Guinea) were collected by fingerprick on
filter paper and stored at room temperature until DNA extraction,
which was carried out using the chelex protocol as described by
Plowe et al. [30].
DNA from the 819 mosquitoes captured in Equatorial Guinea
was extracted using the chelex protocol described by Arez et al.
[31]. DNA from portions head/thorax and abdomen of each
mosquito was extracted separately.
Detection and identification of Plasmodium species
For all samples, detection of malaria infection and identification
of Plasmodium species was made using nested-PCR amplification of
the small subunit ribosomal RNA genes as described by Snounou
et al. [32].
Genotyping of Pvcsp genes
In samples infected with P. vivax, parasite characterisation was
carried out by analysis of the central region of the Pvcsp gene,
following a slightly modified version of the protocol described by
Alves et al. [33]. This was amplified in a MyCyclerTM Thermal
cycler (Biorad), using the primers VivF 59- TCCATCCTG-
TTGGTGGACTT – 39 and VivR 59 – TCACAACGTTAAAT-
ATGCCAG – 39 with final reagent concentrations of 16 reaction
buffer, 1 mM of MgCl2, 100 mM of each dNTPs, 0.5 mM of each
primer and 1 U/ml of Taq DNA Polymerase (Promega), in a total
volume of 50 ml for each reaction. The PCR cycle conditions were:
initial denaturation at 94uC for 5 minutes, followed by 35 cycles of
93uC for 1 minute, 60uC for 90 seconds and 72uC for 1 minute,
with a final extension at 72uC for 10 minutes.
In order to distinguish the three P. vivax strains (VK210, VK247
and P. vivax-like), restriction fragment length polymorphism (RFLP)
analysis was performed using the restriction endonucleases (AluI
and DpnI), following the recommended protocol (New England
Biolabs, Ipswich, MA). PCR-RFLP products were run in a 2%
agarose gel.
Genotyping of Duffy blood group
Duffy genotypes were also determined in P. vivax human
isolates. To detect the point mutation -33T.C, which correspond
to a Duffy-negative phenotype, the DARC gene promoter regions
were amplified by PCR, followed by enzymatic restriction with
StyI (New England Biolabs, Ipswich, MA) (adapted from [13]).
Briefly, the PCR was performed using the primer P38 59-
Figure 1. Map of the five collection places in Equatorial Guinea and Angola. [Footnote: A- Equatorial Guinea; B- Angola; 1- Ngonamanga; 2-
Miyobo; 3- Gabela; 4 – Porto Amboim and 5- Sumbe].
doi:10.1371/journal.pntd.0001192.g001
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AGGCTTGTGCAGGCAGTG - 39 and P39 59- GGCATAGG-
GATAAGGGACT - 39, 0.5 pmol/ml of each, 1 mM of MgCl2,
200 mM of dNTP’s and 1 U/ml of Taq DNA Polymerase
(Promega), in a total volume of 30 ml. Cycling parameters were
as follows: 94uC for 5 minutes, pursued by 30 cycles of 94uC for
1 minute, 59uC for 1 minute and 72uC for 30 seconds, with a final
extension at 72uC for 10 minutes.
Endonuclease StyI was used for RFLP analysis of PCR
products, according to the supplier’s specifications (New England
Biolabs, Ipswich, MA). Restriction fragments were separated on an
18% acrylamide/bis-acrylamide (39.5:1) gel and silver stained.
For confirmation, some samples were purified with the
SureClean Kit (Bioline) according to manufacturer’s recommen-
dations and were sequenced in both directions by Macrogen,
Korea.
Results
Detection and identification of Plasmodium species
The four species of Plasmodium were identified in both countries.
Plasmodium vivax had not been previously described in the mainland
of Equatorial Guinea.
Prevalence of infection in both blood samples and mosquitoes is
presented in Table 1. Regarding the human host, overall
prevalence of infection was much higher in Equatorial Guinea
than in Angola (86.6% versus 28.9%, respectively), with P. falciparum
showing the highest infection rate in both countries (95.2% in
Equatorial Guinea and 97.9% in Angola). Plasmodium vivax was
detected in 15 individuals, 8 from Equatorial Guinea (9.5% of
infected individuals) and 7 from Angola (2.8% of infected
individuals). From these 15 cases, 5 exhibited a single P. vixax
infection, 8 a mixed infection with P. falciparum and 2 a triple
infection with P. falciparum and Plasmodium malariae. In Equatorial
Guinea, the overall prevalence of infected mosquitoes was 26.7%
(219/819). From these, P. vivax infections were found in 10.9%
(24/219), both in head/thorax (salivary glands) and abdomen
(midgut): 22 were a single P. vixax infection and 2 a mixed infection
with P. falciparum.
Genotyping of Pvcsp genes
Using the endonuclease AluI the fragments obtained for the P.
vivax classic were: 243, 135, 133, 108, 90, 78, 57, 54, 30, 27 bp and
for P. vivax VK247 were: 673, 243, 90, 78 bp. Using the
endonuclease DpnI it was possible to identify fragments of 969,
71 and 50 bp in the case of P. vivax classic, and fragments of 360,
225, 108, 81, 71, 54, 50, 27 bp for P. vivax VK247. Fragments
below 50 bp were not considered for variant determination due to
the low molecular weight.
According to this, it was possible to identify 6 blood samples
infected with P. vivax classic, 6 blood samples with P. vivax VK247
and 3 blood samples infected with two strains of P. vivax: classic
and VK247.
No samples were identified as being infected with P. vivax-like. In
this case, it was expected to obtain fragments of 786, 101, 83, 70
and 62 bp when using AluI, and fragments of 883, 169 and 50 bp
when using DpnI.
For the 24 mosquitoes infected with P. vivax, the same procedure
was used for the parasite characterisation but unfortunately no
successful amplification of specific sequences was achieved.
Genotyping of Duffy blood group
All the human isolates P. vivax infected were genotyped for the
Duffy gene by PCR-RFLP (82, 77 and 64 bp for Duffy positive
genotypes and 82, 65, 64 and 12 bp for Duffy negative genotypes;
the fragment of 12 bp was not considered due to the low
molecular weight, not visible in gel). Results showed that all
samples analysed were genotyped as FY*B-33/FY*B-33 (Duffy-
negative homozygous) being therefore classified as Fy(a2b2).
Given that differentiation of bands in acrylamide gel is
sometimes dubious, some samples were sequenced to confirm
results. Sequencing (figure 2) confirmed the Duffy-negative
genotype, since all of them contained the point mutation -
33TRC.
Discussion
Despite all the efforts that have been made to control malaria,
many of them having a real effect, the prevalence of infection is
still very high, even in countries with active control campaigns, like
Equatorial Guinea (86.6%) and Angola (28.9%).
Particularly, P. vivax seems not only to be evolving and adapting,
causing more severe forms of the disease [6,8,34,35,36] but also
appears to be more frequent in countries where either it was not
present or it was not detected by the available techniques in the
past, as is the case of some countries of West and Central Africa
like, Congo [37], Sa˜o Tome´ and Principe [37,38], Gabon [37,39]
and Cameroon [37], becoming a major source of concern. Our
results corroborate these assumptions, since for the first time we
were able to detect P. vivax on mainland Equatorial Guinea in
humans and mosquitoes, which imply well-established whole life-
cycles and active transmission.
Further, a relevant aspect needs to be stressed - the proportion
of P. vivax infected mosquitoes is higher than the proportion of P.
vivax infected individuals. This may be associated with the fact that
in the human host this parasite may be ‘‘hidden’’ since it forms
dormant forms in the liver – hypnozoites - and go unnoticed, being
much more ‘‘visible’’ in mosquitoes. If this is the case, these results
suggest that the prevalence of this species may be underestimated,
not only in this country but in other parts of Africa.
Other factors associated with parasite-human interaction and
immune response could be conditioning this variable prevalence in
P. vivax infection in mosquitoes and human host.
In this study we were able to detect Duffy negative people
carrying P. vivax infections, both in Angola and Equatorial Guinea,
two countries located in West Africa, where the prevalence of
Duffy negative individuals is near 95% [11], confirming thereby
the suspicion of some authors [18,22–25]. Similar results were
Table 1. Prevalence of infection in both humans and
mosquitoes, in Angola and Equatorial Guinea.
Prevalence of
infection Individuals Mosquitoes
Angola Equatorial Guinea
n 898 97 819
Overall infection 28.9% (245/848) 86.6% (84/97) 26.7% (219/819)
Overall infection F 97.9% (240/245) 95.2% (80/84) 89.0% (195/219)
Overall infection V 2.8% (7*/245) 9.5% (8*/84) 10.9% (24/219)
V 3 ind. 2 ind. 22 mosq.
F+V 3 ind. 5 ind. 2 mosq.
F+V+M 1 ind. 1 ind. 0
*All Duffy-negatives.
n - Sample size; F: P. falciparum; V: P. vivax; F+V: mixed infection by P. falciparum
and P. vivax; F+V+M: mixed infection by P. falciparum, P. vivax and P. malariae.
doi:10.1371/journal.pntd.0001192.t001
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found in other studies, but always in areas where the prevalence of
Duffy positive is significantly higher: in Kenya - East Africa [22],
Amazon region in Brazil [23,24] and more recently, in
Madagascar [25].
Me´nard et al. [25] suggested that Duffy positive individuals may
serve as a reservoir of P. vivax providing an opportunity for this
parasite to infect hepatocytes of Duffy negative people and the
selection of new P. vivax strains with capacity to invade Duffy
negative erythrocytes. In the present case, it is likely that the
evolutionary process has been the same, although these two
countries showed low prevalence of Duffy positive autochthonous
individuals. From the beginning of the 90 s, these countries have
experienced a marked increase in economic development with the
finding of important oil reserves. Related to this development,
intensive migration processes are occurring from outside and
inside of the African continent. Therefore, workers from countries
with higher Duffy positive and P. vivax prevalence could be
circulating in Angola and Equatorial Guinea, thus increasing the
reservoir of P. vivax.
Although we do not know which main force was contributing
for the evolution of P. vivax and why it is able to infect Duffy
negative erythrocytes, one thing seems to be clear - P. vivax may
have an extraordinary ability to adapt. In addition, the African
continent has both the ideal temperature and highly competent
vectors for its transmission [3,40]. Altogether, these factors show
that this parasite can become a serious public health problem in
West and Central Africa, both for locals and travelers.
The results obtained in this work are highly relevant. First, it
demonstrates that P. vivax is able to invade erythrocytes using other
receptors than Duffy, and this new capacity is not exclusive of one
strain of P. vivax, since we found samples infected with two different
strains: VK247 and VK210/classic. Other species of Plasmodium, as
Plasmodium knowlesi (phylogenetically close to P. vivax) and P. falciparum
have more than one receptor for the invasion of erythrocytes [41].
Considering that these two phylogenetically distant species have
evolved in order to recognize more than one receptor for erythrocyte
invasion, it is expected that P. vivax is also evolving, becoming capable
of using more than one path of invasion.
Second, this parasite seems to be expanding, and now it can be
found in areas where it was not present in the past. Some
approaches to determine the distribution limits of P. vivax have
been carried out, although areas with high prevalence of Duffy
negative were virtually considered free of this parasite [3]. So it is
expectable that the real distribution of this parasite is greater than
that found by these authors.
In conclusion, this study present the first cases of Duffy negative
individuals infected with different strains of P. vivax (VK247 and
classic) in two West African countries. This finding reinforces the
idea that this parasite is rapidly evolving, being able to use other
receptors than Duffy to invade the erythrocytes.
The presence of P. vivax infection both in blood samples and
mosquitoes indicates that this parasite is well adapted. Further, the
higher number of infected mosquitoes shows that this species is
more ‘‘visible’’ in mosquitoes and may go unnoticed if blood
samples are only analyzed.
It is therefore important to establish the real distribution of P.
vivax, since new and more aggressive cases of infection by this
parasite are reported every day, in countries where this parasite
has not been noticed before having significant implications in the
design of control measures and implementation of prophylactic
and therapeutic regimens.
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